Iyer Smita S, Gangadhara Sailaja, Victor Blandine, Gomez Rosy, Basu Rahul, Hong Jung Joo, Labranche Celia, Montefiori David C, Villinger Francois, Moss Bernard, Amara Rama Rao
Division of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
Department of Surgery, Duke University, Durham, NC 27705;
J Immunol. 2015 Aug 1;195(3):994-1005. doi: 10.4049/jimmunol.1500083. Epub 2015 Jun 26.
The goal of an HIV vaccine is to generate robust and durable protective Ab. Vital to this goal is the induction of CD4(+) T follicular helper (TFH) cells. However, very little is known about the TFH response to HIV vaccination and its relative contribution to magnitude and quality of vaccine-elicited Ab titers. In this study, we investigated these questions in the context of a DNA/modified vaccinia virus Ankara SIV vaccine with and without gp140 boost in aluminum hydroxide in rhesus macaques. In addition, we determined the frequency of vaccine-induced CD4(+) T cells coexpressing chemokine receptor, CXCR5 (facilitates migration to B cell follicles) in blood and whether these responses were representative of lymph node TFH responses. We show that booster modified vaccinia virus Ankara immunization induced a distinct and transient accumulation of proliferating CXCR5(+) and CXCR5(-) CD4 T cells in blood at day 7 postimmunization, and the frequency of the former but not the latter correlated with TFH and B cell responses in germinal centers of the lymph node. Interestingly, gp140 boost induced a skewing toward CXCR3 expression on germinal center TFH cells, which was strongly associated with longevity, avidity, and neutralization potential of vaccine-elicited Ab response. However, CXCR3(+) cells preferentially expressed the HIV coreceptor CCR5, and vaccine-induced CXCR3(+)CXCR5(+) cells showed a moderate positive association with peak viremia following SIV251 infection. Taken together, our findings demonstrate that vaccine regimens that elicit CXCR3-biased TFH cell responses favor Ab persistence and avidity but may predispose to higher acute viremia in the event of breakthrough infections.
HIV疫苗的目标是产生强大且持久的保护性抗体。对于这一目标至关重要的是诱导CD4(+)滤泡辅助性T细胞(TFH细胞)。然而,关于TFH对HIV疫苗接种的反应及其对疫苗诱导抗体滴度的数量和质量的相对贡献,我们了解得非常少。在本研究中,我们在恒河猴中研究了在有或没有用氢氧化铝佐剂加强免疫gp140的情况下,DNA/改良安卡拉痘苗病毒SIV疫苗背景下的这些问题。此外,我们确定了血液中同时表达趋化因子受体CXCR5(促进向B细胞滤泡迁移)的疫苗诱导CD4(+)T细胞的频率,以及这些反应是否代表淋巴结TFH反应。我们发现,加强免疫改良安卡拉痘苗病毒在免疫后第7天诱导血液中增殖的CXCR5(+)和CXCR5(-)CD4 T细胞出现明显且短暂的积累,前者而非后者的频率与淋巴结生发中心的TFH和B细胞反应相关。有趣的是,gp140加强免疫诱导生发中心TFH细胞向CXCR3表达偏移,这与疫苗诱导抗体反应的持久性、亲和力和中和潜力密切相关。然而,CXCR3(+)细胞优先表达HIV共受体CCR5,并且疫苗诱导的CXCR3(+)CXCR5(+)细胞与SIV251感染后的病毒血症峰值呈中度正相关。综上所述,我们的研究结果表明,引发偏向CXCR3的TFH细胞反应的疫苗方案有利于抗体的持久性和亲和力,但在发生突破性感染时可能易导致更高的急性病毒血症。